Fibroblast growth factor (FGF) 
Introduction

Inorganic phosphate is an essential and the most abundant anion in our body. Phosphate is one of the major components of bone as hydroxyapatite [Ca10(PO4)6(OH)2], a constituent of the cell membrane and works in various cellular functions as numerous phosphorylated metabolites. In order to accomplish these functions, it seems to be necessary that the circulatory phosphate level is regulated to within a narrow range. While the regulatory mechanisms of the serum calcium level have been extensively studied and explained by actions of two calcium-regulating hormones, parathyroid hormone (PTH) and 1,25-dihydroxyvitamin D[1,25(OH)2D], it has been largely unknown how the serum phosphate level is maintained. Recent identification of fibroblast growth factor (FGF) 23 indicated that the serum phosphate level is regulated by a humoral mechanism and FGF23 plays an essential role in the maintenance of the serum phosphate level. In addition, several disorders of phosphate metabolism have been shown to be caused by deranged actions of FGF23.
Regulation of the Serum Phosphate Level
The serum phosphate level is regulated by intestinal phosphate absorption, renal phosphate reabsorption and dynamic equilibrium between extracellular phosphate and intracellular phosphate or phosphate in bone (Fig. 1 -X-X-Ar g 1 7 9 mo t i f .
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tion of phosphate (1) (Fig. 2) .
Structure of FGF23
Sequence of cDNA for FGF23 indicates that FGF23 is a protein with 251 amino acids (Fig. 2). There is a signal peptide with 24 amino acids in the N-terminal portion of FGF
FGF23 knockout mice were created to examine whether FGF23 has physiological functions (12, 13 (19, 20) . However, the mechanisms of excess actions of FGF23 in these diseases are variable (Table 1) . (11, 25) .
Involvement of FGF23 in the Development of Hypophosphatemic Rickets/Osteomalacia
As mentioned before, ADHR, ARHR, XLH, TIO and hypophosphatemic rickets / osteomalacia associated with McCune-Albright syndrome/fibrous dysplasia are characterized by hypophosphatemia and rather low 1,25(OH)2D levels. These biochemical features are those expected to be caused by excess actions of FGF23. Actually, after the cloning of FGF23, several enzyme-linked immunosorbent assays for FGF23 have been established. These assays confirmed that FGF23 levels are basically high in patients with these hypophosphatemic diseases
FGF23 was cloned from a tumor responsible for TIO (6). This disease has a profound effect on the quality of life of the patients. Because of severe muscle weakness and bone pain, patients with TIO sometimes become completely bedridden. However, this disease is cured by complete resection of responsible tumors. Circulatory FGF23 level is elevated in virtually all patients with TIO, and rapidly decreases into or below the reference range after removal of the responsible tumors (20-22). In addition, it has been shown that tumors causing TIO strongly express FGF23 (6, 23). Therefore, TIO is considered to be caused by overexpression of FGF23 in responsible tumors. Most tumors causing TIO are now pathologically classified as phosphaturic mesenchymal tumor (mixed connective tissue variant) (PMTMCT) (24
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This resistance to the processing was expected to cause increased amount of biologically active full-length FGF23 and enhanced activity of FGF23. However, FGF23 level is not always high in patients with ADHR. FGF23 level fluctuates in these patients and it was reported that high FGF23 level is associated with hypophosphatemia (26). These results suggest that mutations in FGF 23 gene somehow impair the regulatory mechanism of FGF 23 production and dysregulated FGF23 production underlie hypophosphatemia in patients with ADHR.
Responsible genes for XLH and ARHR are phosphateregulating gene with homologies to endopeptidases on the X chromosome (PHEX) (27) and dentin matrix protein 1 (DMP 1) (28, 29) (28, 30) . Together with elevated FGF23 levels in patients with these diseases (19) (20) (21) 28) 
FGF23 and Hyperphosphatemic Diseases
it was a surprise that GALNT3 encoding UDP-N-acetyl-alpha-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase 3 (ppGaNTase-T3) was first reported to be responsible for hyperphosphatemic tumoral calcinosis (33). ppGaNTase-T3 is an enzyme that transfers N-acetylgalactosamine from UDP-N-acetyl-alpha-D-galactosamine to serine or threonine residue as an initial sugar of mucin-type O-linked glycosylation. However, it was unclear how mutations in GALNT3 gene cause hyperphosphatemia. There are several assay methods for FGF23. Intact assay uses two monoclonal antibodies that recognize Nterminal and C-terminal potion of the processing site of FGF23 and detects only full-length uncleaved FGF23 (20). On the other hand, C-terminal assay uses two kinds of polyclonal antibodies to the C-terminal region of the processing site and measures both full-length and cleaved C-terminal fragment of FGF23 (19). FGF23 levels evaluated by these two assays correlate very well in patients with XLH (21).
However, when FGF23 levels in patients with GALNT3 mutations were analyzed by these two assays, it was found that FGF23 was quite high by C-terminal assay, but low-low normal in intact assay (34) (35) . In addition, silencing ppGaNTase-T3 expression enhanced the processing of FGF23 protein (34) T a b l e 2 . Hy p e r p h o s p h a t e mi c T u mo r a l Ca l c i n o s i s a n d Ci r c u l a t o r y F GF 2 3 L e v e l 
